Wei Cui

Dr. Wei Cui


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
YDYi Deng
Yi Deng
YLYongyu Li
Yongyu Li
RXRongde Xu
Rongde Xu
JLJing Li
Jing Li
WCWei Cui
Wei Cui
Letter to the Editor The critical role of PD-L1 expression in immunotherapy for advanced non-small cell lung cancer Yi Deng, Yongyu Li, Rongde Xu, Jing Li, Wei Cui

1 November 2026 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
YDYi Deng
Yi Deng
YLYanqing Le
Yanqing Le
JLJing Li
Jing Li
RXRongde Xu
Rongde Xu
WCWei Cui
Wei Cui
Drug-eluting bead bronchial artery chemoembolization (DEB-BACE) has been investigated as a locoregional salvage treatment for advanced non-small cell lung cancer (NSCLC). It may be considered for treatment-refractory or symptomatic central tumors. We retrospectively describe case of three patients with centrally located, treatment-refractory NSCLC who underwent DEB-BACE. All three subsequently expectorated soft-tissue material. Clinical features, procedures, imaging, pathology, and outcomes were reviewed. Potential bronchial and non-bronchial systemic tumor-feeding arteries were assessed using contrast-enhanced computed tomography and selective digital subtraction angiography (DSA). Lobaplatin was infused intra-arterially. Embolization was then performed with 300 to 500 μm epirubicin-loaded Bead microspheres. The procedural endpoint was marked reduction of tumor blush with stasis or near-stasis. One patient had SMARCA4-deficient NSCLC. Two had squamous cell carcinoma. Soft-tissue expectoration occurred 3 days to 2 weeks after DEB-BACE. Histopathology confirmed carcinoma with extensive necrosis in Cases 1 and 2. Pathological confirmation was unavailable in Case 3. Case 1 achieved a durable partial response during repeated DEB-BACE and continued sintilimab treatment. The tumor decreased from 94 mm × 55 mm to 22 mm × 14 mm at 13 months and remained stable at 29 months. Case 2 developed tumor expectoration 3 days after treatment. Bronchial patency was subsequently restored. The patient died 10 months after diagnosis. Case 3 developed recurrent hemoptysis and underwent emergency hemostatic bronchial artery embolization. The patient subsequently expectorated a soft-tissue mass and died from progressive pulmonary infection 14 months after diagnosis. Tumor expectoration may represent treatment-associated necrosis after DEB-BACE. Careful assessment of vascular anatomy, bleeding risk, infection, and non-target embolization risk is essential.